BlackRock’s Intersect ENT, Inc XENT Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2022
Q2
Sell
-2,629,605
Closed -$73.7M 6098
2022
Q1
$73.7M Sell
2,629,605
-8,728
-0.3% -$239K ﹤0.01% 2332
2021
Q4
$72.1M Buy
2,638,333
+44,498
+2% +$1.21M ﹤0.01% 2421
2021
Q3
$70.6M Sell
2,593,835
-362,503
-12% -$8.96M ﹤0.01% 2425
2021
Q2
$50.5M Sell
2,956,338
-18,824
-0.6% -$352K ﹤0.01% 2696
2021
Q1
$62.1M Buy
2,975,162
+89,386
+3% +$2.06M ﹤0.01% 2482
2020
Q4
$66.1M Buy
2,885,776
+235,862
+9% +$4.49M ﹤0.01% 2307
2020
Q3
$43.2M Sell
2,649,914
-68,156
-3% -$1.23M ﹤0.01% 2383
2020
Q2
$36.8M Buy
2,718,070
+123,355
+5% +$1.44M ﹤0.01% 2427
2020
Q1
$30.7M Sell
2,594,715
-54,015
-2% -$1.2M ﹤0.01% 2363
2019
Q4
$66M Buy
2,648,730
+190,196
+8% +$3.85M ﹤0.01% 2196
2019
Q3
$41.8M Buy
2,458,534
+78,100
+3% +$1.42M ﹤0.01% 2403
2019
Q2
$54.2M Sell
2,380,434
-3,248
-0.1% -$87.6K ﹤0.01% 2274
2019
Q1
$76.6M Sell
2,383,682
-77,404
-3% -$2.4M ﹤0.01% 2040
2018
Q4
$69.4M Sell
2,461,086
-145,997
-6% -$4.28M ﹤0.01% 2039
2018
Q3
$75M Buy
2,607,083
+296,973
+13% +$8.92M ﹤0.01% 2156
2018
Q2
$86.5M Buy
2,310,110
+371,831
+19% +$14.6M ﹤0.01% 2041
2018
Q1
$76.2M Sell
1,938,279
-42,663
-2% -$1.56M ﹤0.01% 2017
2017
Q4
$64.2M Buy
1,980,942
+39,761
+2% +$1.19M ﹤0.01% 2131
2017
Q3
$60.5M Sell
1,941,181
-3,732
-0.2% -$110K ﹤0.01% 2169
2017
Q2
$54.4M Buy
1,944,913
+300,920
+18% +$6.81M ﹤0.01% 2197
2017
Q1
$28.2M Buy
1,643,993
+1,641,917
+79,090% +$23M ﹤0.01% 2558
2016
Q4
$25K Sell
2,076
-7,245
-78% -$93.8K ﹤0.01% 3195
2016
Q3
$147K Sell
9,321
-3,699
-28% -$55.7K ﹤0.01% 2360
2016
Q2
$168K Buy
13,020
+12,010
+1,189% +$188K ﹤0.01% 2207
2016
Q1
$19K Sell
1,010
-229
-18% -$4.15K ﹤0.01% 2886
2015
Q4
$28K Buy
1,239
+900
+265% +$17.8K ﹤0.01% 2401
2015
Q3
$8K Hold
339
﹤0.01% 2852
2015
Q2
$10K Buy
+339
New +$8.88K ﹤0.01% 2813

BlackRock's XENT Position: Q2 2022 in Review

BlackRock sold out of Intersect ENT, Inc (XENT) in Q2 2022, closing a stake of 2,629,605 shares — an estimated $73.7M sold.

BlackRock first reported a position in XENT in Q2 2015 and held it in 28 quarters. The position peaked at $86.5M in Q2 2018. 0 funds tracked by Wall St. Rank hold XENT as of Q2 2022.

  • BlackRock reported no remaining Intersect ENT, Inc position as of Q2 2022 after selling out during the quarter.
  • BlackRock sold 2,629,605 Intersect ENT, Inc shares in Q2 2022, an estimated $73.7M.
  • BlackRock first reported a position in Intersect ENT, Inc in Q2 2015 and held it in 28 quarters.
  • BlackRock's Intersect ENT, Inc position peaked at $86.5M in Q2 2018.
  • 0 funds tracked by Wall St. Rank held Intersect ENT, Inc as of Q2 2022.

Based on BlackRock's 13F filing for Q2 2022, filed 12 Aug 2022.